Form 4 for AKTS Aktis Oncology, Inc.
Accepted 2026-09-24 16:05:05 ET · period of report 2026-09-23 · accession 0001193125-26-401014 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-24 16:05 | 2026-09-23 | AKTS | Czibere Akos | Chief Medical Off | M - OptEx | $4.95 | +12.5K | 12.5K | New | +$61.9K |
| DMT | 2026-09-24 16:05 | 2026-09-23 | AKTS | Czibere Akos | Chief Medical Off | S - Sale+OE | $20.69 | -12.5K | 0 | -100% | -$258.6K |
| DT | 2026-09-24 16:05 | 2026-09-23 | AKTS | Czibere Akos | Chief Medical Off | M - OptEx | $0.00 | -12.5K | 208.7K | -6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-23 | M | A | 12,500 | $4.95 | 12,500 | D | — | — | (F1) The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2026. |
| 2 | Common | Common Stock | 2026-09-23 | S | D | 5,099 | $20.19 | 7,401 | D | — | — | (F1) The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2026. (F2) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.6700 to $20.6500, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 3 | Common | Common Stock | 2026-09-23 | S | D | 7,401 | $21.03 | 0 | D | — | — | (F1) The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2026. (F3) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.6700 to $21.5000, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-09-23 | M | D | 12,500 | $0.00 | 208,718 | D | $4.95 · — to 2034-06-30 | 12,500 Common Stock | (F1) The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2026. (F4) 25% of the original number of shares subject to the option vested on July 1, 2025, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive. |